Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

Giacomo Tini; Edoardo Bertero; Alessio Signori; Maria Pia Sormani; Christoph Maack; Rudolf A. De Boer; Marco Canepa; Pietro Ameri

doi:10.1161/JAHA.119.016309

Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

Giacomo Tini, Edoardo Bertero, Alessio Signori, Maria Pia Sormani, Christoph Maack, Rudolf A. De Boer, Marco Canepa, Pietro Ameri^*

^*Corresponding author for this work

Cardiovascular Centre (CVC)

Research output: Contribution to journal › Review article › peer-review

30 Citations (Scopus)

91 Downloads (Pure)

Abstract

Background The burden of cancer in heart failure with reduced ejection fraction is apparently growing. Randomized controlled trials (RCTs) may help understanding this observation, since they span decades of heart failure treatment. Methods and Results We assessed cancer, cardiovascular, and total mortality in phase 3 heart failure RCTs involving >= 90% individuals with left ventricular ejection fraction

Original language	English
Article number	016309
Number of pages	29
Journal	Journal of the American Heart Association
Volume	9
Issue number	18
DOIs	https://doi.org/10.1161/JAHA.119.016309
Publication status	Published - 15-Sept-2020

Keywords

cancer
comorbidities
heart failure
mortality
CARDIAC-RESYNCHRONIZATION THERAPY
VENTRICULAR SYSTOLIC FUNCTION
CONVERTING-ENZYME INHIBITORS
RANDOMIZED-TRIAL
INSUFFICIENCY BISOPROLOL
DEFIBRILLATOR IMPLANTATION
ASYMPTOMATIC PATIENTS
VASODILATOR THERAPY
INCREASED RISK
ACCLAIM TRIAL

Access to Document

10.1161/JAHA.119.016309Licence: CC BY-NC-ND

Cancer Mortality in Trials of Heart Failure With Reduced Ejection FractionFinal publisher's version, 867 KBLicence: CC BY-NC-ND

Handle.net

Persistent link

Cite this

@article{86c1e7aeb1c34c10ae6af6199b516d40,

title = "Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis",

abstract = "Background The burden of cancer in heart failure with reduced ejection fraction is apparently growing. Randomized controlled trials (RCTs) may help understanding this observation, since they span decades of heart failure treatment. Methods and Results We assessed cancer, cardiovascular, and total mortality in phase 3 heart failure RCTs involving >= 90% individuals with left ventricular ejection fraction",

keywords = "cancer, comorbidities, heart failure, mortality, CARDIAC-RESYNCHRONIZATION THERAPY, VENTRICULAR SYSTOLIC FUNCTION, CONVERTING-ENZYME INHIBITORS, RANDOMIZED-TRIAL, INSUFFICIENCY BISOPROLOL, DEFIBRILLATOR IMPLANTATION, ASYMPTOMATIC PATIENTS, VASODILATOR THERAPY, INCREASED RISK, ACCLAIM TRIAL",

author = "Giacomo Tini and Edoardo Bertero and Alessio Signori and Sormani, {Maria Pia} and Christoph Maack and {De Boer}, {Rudolf A.} and Marco Canepa and Pietro Ameri",

year = "2020",

month = sep,

day = "15",

doi = "10.1161/JAHA.119.016309",

language = "English",

volume = "9",

journal = "Journal of the American Heart Association",

issn = "2047-9980",

publisher = "Wiley",

number = "18",

}

TY - JOUR

T1 - Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction

T2 - A Systematic Review and Meta-Analysis

AU - Tini, Giacomo

AU - Bertero, Edoardo

AU - Signori, Alessio

AU - Sormani, Maria Pia

AU - Maack, Christoph

AU - De Boer, Rudolf A.

AU - Canepa, Marco

AU - Ameri, Pietro

PY - 2020/9/15

Y1 - 2020/9/15

N2 - Background The burden of cancer in heart failure with reduced ejection fraction is apparently growing. Randomized controlled trials (RCTs) may help understanding this observation, since they span decades of heart failure treatment. Methods and Results We assessed cancer, cardiovascular, and total mortality in phase 3 heart failure RCTs involving >= 90% individuals with left ventricular ejection fraction

AB - Background The burden of cancer in heart failure with reduced ejection fraction is apparently growing. Randomized controlled trials (RCTs) may help understanding this observation, since they span decades of heart failure treatment. Methods and Results We assessed cancer, cardiovascular, and total mortality in phase 3 heart failure RCTs involving >= 90% individuals with left ventricular ejection fraction

KW - cancer

KW - comorbidities

KW - heart failure

KW - mortality

KW - CARDIAC-RESYNCHRONIZATION THERAPY

KW - VENTRICULAR SYSTOLIC FUNCTION

KW - CONVERTING-ENZYME INHIBITORS

KW - RANDOMIZED-TRIAL

KW - INSUFFICIENCY BISOPROLOL

KW - DEFIBRILLATOR IMPLANTATION

KW - ASYMPTOMATIC PATIENTS

KW - VASODILATOR THERAPY

KW - INCREASED RISK

KW - ACCLAIM TRIAL

U2 - 10.1161/JAHA.119.016309

DO - 10.1161/JAHA.119.016309

M3 - Review article

SN - 2047-9980

VL - 9

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

IS - 18

M1 - 016309

ER -

Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this